

Figure 1




FIG. 2. Drug release profiles of the three examples.

Figure 2




Figure 3




Figure 4




Figure 5




Figure 6




Figure 7




Figure 8




Figure 9



Mean Plasma Concentration-time Profiles of Lovastatin and Lovastatin Acid In Patients (n=12) after Multiple-dose Administration of Lovastatin XL or MEVACOR




Figure 11

Mean Plasma Concentration-time Profiles of Total and Active Inhibitors of HMG-CoA Reductase in Patients (n=12) after Multiple-dose Administration of Lovastatin XL or MEVACOR

Day 1

- Total HMG-CoA reductase inhibitors after lovastatin XL
- Total HMG-CoA reductase inhibitors after MEVACOR
- △ Active HMG-CoA reductase inhibitors after lovastatin XL
- ▲ Active HMG-CoA reductase inhibitors after MEVACOR

Day 28




FIGURE 12




FIGURE 13

